Compare SNOA & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOA | CLGN |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 7.0M |
| IPO Year | 2006 | 2015 |
| Metric | SNOA | CLGN |
|---|---|---|
| Price | $1.20 | $0.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 90.9K | 40.1K |
| Earning Date | 06-16-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,529,000.00 | N/A |
| Revenue This Year | $23.00 | $240.45 |
| Revenue Next Year | $24.59 | $38.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.68 | N/A |
| 52 Week Low | $0.85 | $0.27 |
| 52 Week High | $6.92 | $3.23 |
| Indicator | SNOA | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 40.74 |
| Support Level | $1.02 | $0.29 |
| Resistance Level | $1.25 | $0.44 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 20.00 | 14.73 |
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.